ADIA Nutrition Inc. to Host Webinar on HSCT for MS and Autoimmune Conditions with HSCT Warriors
Winter Park, Florida--(Newsfile Corp. - November 19, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) invites all shareholders, supporters, and potential investors to join a live webinar tomorrow, Thursday, November 20, 2025, at 6:30 PM EST, hosted by HSCT Warriors.
Healthcare and Hospitals, Health
2025-11-19 9:30 AM EST | Adia Nutrition Inc.
Edison Issues Report on Tradedoubler (TRAD)
London, United Kingdom--(Newsfile Corp. - November 19, 2025) - Edison issues report on Tradedoubler (OMX: TRAD). Tradedoubler has a strong proposition in performance marketing, with particular strengths in the partner (affiliate) and influencer areas. With the springboard of a leading position in Europe, it is now expanding operations into the US, the largest global advertising market. Its influencer marketing business, Metapic, is well-placed to take advantage of this dynamic and fast-
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-11-19 8:48 AM EST | Edison Group
Rock Salt Marketing Launches AI SEO Services for LLM Search Visibility
Salt Lake City, Utah--(Newsfile Corp. - November 19, 2025) - Award-winning Utah- and Nashville-based digital marketing agency, Rock Salt Marketing Cooperative, has officially launched its new AI SEO services as an add-on to its traditional SEO program, designed to help businesses nationwide improve visibility and performance across large language models (LLMs).
Real Estate, Travel, Health, Legal
2025-11-19 7:50 AM EST | Rock Salt Marketing Cooperative
Red Light Holland's FDA-Compliant, DEA-Registered Partner Irvine Labs Receives Second, Larger 5kg Psilocybin Shipment via USA Controlled Substances Import Permit
Toronto, Ontario--(Newsfile Corp. - November 19, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal, recreational market within the Netherlands, in compliance with all applicable laws is excited to announce that it has, f
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-11-19 7:45 AM EST | Red Light Holland Corp.
Glow Lifetech Achieves Debt-Free Status, Strengthening Balance Sheet and Enhancing Financial Flexibility for Growth
Toronto, Ontario--(Newsfile Corp. - November 19, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it has achieved debt-free status, eliminating all outstanding debt and further strengthening its already strong balance sheet and financial flexibility. This milestone marks an important step in Glow's ongoing commitment to disciplined financial management positioning the business for long-term sustainable growth
2025-11-19 7:30 AM EST | Glow Lifetech Corp.
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations. Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as
Biotechnology, Pharmaceuticals, Health
2025-11-19 3:15 AM EST | Defence Therapeutics Inc.
Hemostemix Closes CDN$280,594 Private Placement
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida
Biotechnology, Pharmaceuticals, Health
2025-11-18 5:08 PM EST | Hemostemix Inc.
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it is conducting a non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other accredited inves
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-18 4:42 PM EST | NervGen Pharma Corp.
AmeriHealth Caritas Foundation Awards $1.9 Million in Grants to Advance the Well-Being of Children and Families
Newtown Square, Pennsylvania--(Newsfile Corp. - November 18, 2025) - The AmeriHealth Caritas Foundation awarded grants totaling $1.9 million to nonprofits delivering housing stability, health care access, and parenting support to reduce the impact of adverse childhood experiences. The funding supports 16 organizations across eight states and the District of Columbia with initiatives aiming to strengthen families, increase ch
Healthcare and Hospitals, Health
2025-11-18 11:30 AM EST | AmeriHealth Caritas Foundation
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference from December 11-14, 2025 in Key West, Florida. The company will highlight its world-leading angiogenic cell therapy, ACP-01, which regenerates circulation, heals ulcers, alleviates pain, and improves quality of life for patients with advanced wound care needs including Peri
Biotechnology, Pharmaceuticals, Health
2025-11-18 11:30 AM EST | Hemostemix Inc.
AAMI Updates Medical Device Design Standard for First Time Since 2009
Arlington, Virginia--(Newsfile Corp. - November 18, 2025) - How medical professionals interact with medical devices is an increasingly vital consideration for the manufacturers who design those medical devices. The Association for the Advancement of Medical Instrumentation (AAMI) has updated its primary human factors engineering guidance for the medical device industry for the first time in over fifteen years.
2025-11-18 8:54 AM EST | Association for the Advancement of Medical Instrumentation
DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") Further to its press release from June 3, 2025 and October 24, 2025, the Company is pleased to announce that it has closed its non-brokered private placement of units ("Units") with each Unit consisting of one common share in the capital of the Company (each a "Share") an
2025-11-18 8:30 AM EST | DiagnosTear Technologies Inc.
Aleen Inc. Identifies Core Insights from Concept Testing Phase
Toronto, Ontario--(Newsfile Corp. - November 18, 2025) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announced the completion of its initial concept testing for the upcoming Smart Analytics feature. The research provided valuable insight into how users interact with wellness tools and what they expect from digital self-awareness platforms. The findings revealed three consistent user priorities: Clear visualization of personal wellness patterns; Strong privac
2025-11-18 8:08 AM EST | Aleen Inc.
TempraMed Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "9DY." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 3 months, commencing on November 18, 2025
Technology, Biotechnology, Pharmaceuticals, Health
2025-11-18 7:00 AM EST | TempraMed Technologies Ltd
FendX and Aquaox Sign MOU to Pursue Innovation in Sustainable Pathogen Elimination
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has signed a Memorandum of Understanding ("MOU") dated November 17, 2025 with Aquaox LLC ("Aquaox"), a U.S. based manufactu
Technology, Healthcare and Hospitals, Health
2025-11-18 6:30 AM EST | FendX Technologies Inc.
Predictmedix AI Announces Closing of $460,150 First Tranche
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce the successful closing of the first tranche of its non-brokered private placement. The Company issued 9,203,000 units ("Units") at an issue price of $0.05 per Unit, raising gross proceeds of $460,150. Notably, $60,000 of the tranche was subscribed by insid
2025-11-17 5:02 PM EST | QScreen AI Inc.
Mobile-health Network Solutions Co-CEO Teoh Pui Pui Increases Equity Stake Through Open Market Purchase
Singapore, Singapore--(Newsfile Corp. - November 17, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI HealthTech platform, today announced that its co-founder, co-CEO, COO, and Chairwoman of the Board, Dr. Teoh Pui Pui, has acquired additional shares of the company's Class A Ordinary Shares through an independent open market transaction. According to a Schedule 13D filed today with the U.S. Securities and Exchange Commis
2025-11-17 4:30 PM EST | Mobile-health Network Solutions
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:45 AM EST | Phio Pharmaceuticals Corp.
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank of Canada as administrative agent. The credit agreement provides for a US$21.0 million term loan facility and a US$5.0 million revolving loan facility. The term loan facility benefits from an additional US$10.0 million delayed draw feature, intended to finance future licensing and acquisitio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:30 AM EST | Medexus Pharmaceuticals Inc.
ADIA Nutrition Inc. Requests SIC Code Update to 2836 (Biological Products) with SEC and OTC Markets
Winter Park, Florida--(Newsfile Corp. - November 17, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced it has filed with the SEC to update its Standard Industrial Classification (SIC) code from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) and with OTC Markets to update from 6719 (Holding Companies, N.E.C.) to 2836 (Biological Products, Except Diagnostic), accurately reflecting its core business of manufacturin
Healthcare and Hospitals, Health
2025-11-17 8:00 AM EST | Adia Nutrition Inc.